Blueprint Medicines Corp
BPMC98.050USD
+8.549+9.55%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
6.25BCap. mercado
PérdidaP/E TTM
Más Datos de Blueprint Medicines Corp Compañía
Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Información de la empresa
Código de la empresaBPMC
Nombre de la empresaBlueprint Medicines Corp
Fecha de salida a bolsaApr 30, 2015
Fundada en2008
Director ejecutivoMs. Kathryn D (Kate) Haviland
Número de empleados649
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 30
Dirección45 Sidney Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02139
Teléfono16173747580
Sitio Webhttps://www.blueprintmedicines.com/
Código de la empresaBPMC
Fecha de salida a bolsaApr 30, 2015
Fundada en2008
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Chairman of the Board
Chairman of the Board
142.51K
+4.75%
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
73.23K
+22.22%
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
44.19K
+15.24%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
43.17K
+20.54%
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
42.00K
+20.92%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Dr. Christopher K. Murray, Ph.D.
Dr. Christopher K. Murray, Ph.D.
Executive Vice President, Chief Technical Operations and Quality Officer
Executive Vice President, Chief Technical Operations and Quality Officer
28.60K
+48.63%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
23.94K
-13.94%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.09K
+56.18%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
+19.95%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Chairman of the Board
Chairman of the Board
142.51K
+4.75%
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
73.23K
+22.22%
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
44.19K
+15.24%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
43.17K
+20.54%
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
42.00K
+20.92%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Desglose de ingresos
Divisa: USDHora de actualización: dom., 6 de abr
Divisa: USDHora de actualización: dom., 6 de abr
FY2024Q3
FY2024Q2
FY2024Q1
Por negocioUSD
Nombre
Ganancia
Proporción
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
113.13M
88.26%
Rest of the world
15.05M
11.74%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
Accionista
Hora de actualización: dom., 23 de feb
Hora de actualización: dom., 23 de feb
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
The Vanguard Group, Inc.
10.47%
T. Rowe Price Associates, Inc.
8.70%
BlackRock Institutional Trust Company, N.A.
7.74%
Wellington Management Company, LLP
6.63%
State Street Global Advisors (US)
3.87%
Other
62.58%
Estadísticas de accionistas
Accionista
Proporción
The Vanguard Group, Inc.
10.47%
T. Rowe Price Associates, Inc.
8.70%
BlackRock Institutional Trust Company, N.A.
7.74%
Wellington Management Company, LLP
6.63%
State Street Global Advisors (US)
3.87%
Other
62.58%
Tipo
Accionista
Proporción
Investment Advisor/Hedge Fund
49.33%
Investment Advisor
40.93%
Hedge Fund
10.05%
Research Firm
2.72%
Sovereign Wealth Fund
1.10%
Individual Investor
1.08%
Venture Capital
1.04%
Pension Fund
0.55%
Bank and Trust
0.45%
Participación institucional
Hora de actualización: lun., 24 de feb
Hora de actualización: lun., 24 de feb
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
658
69.72M
107.98%
-1.29M
2024Q4
657
69.17M
108.25%
-2.83M
2024Q3
644
67.12M
105.97%
-7.85M
2024Q2
622
68.23M
108.95%
-6.94M
2024Q1
615
67.81M
110.73%
-5.62M
2023Q4
612
65.87M
108.35%
-10.02M
2023Q3
602
66.47M
109.56%
-7.64M
2023Q2
614
65.78M
108.78%
-8.60M
2023Q1
625
65.63M
109.42%
-10.28M
2022Q4
635
64.56M
107.90%
-8.82M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
6.76M
10.58%
+90.23K
+1.35%
Dec 31, 2024
T. Rowe Price Associates, Inc.
5.62M
8.79%
+315.30K
+5.94%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.00M
7.82%
+13.26K
+0.27%
Dec 31, 2024
Wellington Management Company, LLP
4.28M
6.7%
+316.75K
+7.99%
Dec 31, 2024
State Street Global Advisors (US)
2.50M
3.91%
-265.50K
-9.60%
Dec 31, 2024
William Blair Investment Management, LLC
1.94M
3.04%
+269.90K
+16.12%
Dec 31, 2024
Fidelity Management & Research Company LLC
1.69M
2.64%
-1.98M
-53.96%
Dec 31, 2024
Geode Capital Management, L.L.C.
1.49M
2.33%
+9.91K
+0.67%
Dec 31, 2024
Macquarie Investment Management
1.26M
1.97%
-4.68K
-0.37%
Dec 31, 2024
Avoro Capital Advisors LLC
1.19M
1.85%
+1.19M
--
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
Invesco Biotechnology & Genome ETF
2.8%
WisdomTree BioRevolution Fund
2.56%
Tema Oncology ETF
2.52%
Range Cancer Immunotherapy ETF
1.97%
SPDR S&P Biotech ETF
1.82%
Virtus LifeSci Biotech Products ETF
1.68%
Direxion Daily S&P Biotech Bull 3X Shares
1.16%
American Century Focused Dynamic Growth ETF
1.02%
iShares Health Innovation Active ETF
0.88%
JPMorgan Fundamental Data Science Small Core ETF
0.88%
Ver más
Invesco Biotechnology & Genome ETF
Proporción2.8%
WisdomTree BioRevolution Fund
Proporción2.56%
Tema Oncology ETF
Proporción2.52%
Range Cancer Immunotherapy ETF
Proporción1.97%
SPDR S&P Biotech ETF
Proporción1.82%
Virtus LifeSci Biotech Products ETF
Proporción1.68%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción1.16%
American Century Focused Dynamic Growth ETF
Proporción1.02%
iShares Health Innovation Active ETF
Proporción0.88%
JPMorgan Fundamental Data Science Small Core ETF
Proporción0.88%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos